It increases their costs and thus risks. Remember if their costs get to high they can't afford to buy new patents and there is a ticking clock before their current portfolio is worthless.
Yes. :-) Not sure if you meant to reply to me or another commenter.
My fault for not being clear. I was responding to "But this isn't too broad." I agree this case is not directly important, but it will have a fair amount of indirect impact based on the award size if nothing else.